<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>&lt;i&gt;Helicobacter&lt;/i&gt; &lt;i&gt;pylori&lt;/i&gt;: Diagnosis and management in the pediatric patient</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center"><i>Helicobacter</i> <i>pylori</i>: Diagnosis and management in the pediatric patient</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle"><i>Helicobacter</i> <i>pylori</i>: Diagnosis and management in the pediatric patient</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Benjamin D Gold, MD, FAAP, FACG</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nicola L Jones, MD, FRCPC, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">B UK Li, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Melvin B Heyman, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 26, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H18820429"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Chronic infection with <em>Helicobacter</em> <em>pylori</em> is an important cause of gastrointestinal pathology in adults and children. However, severe gastroduodenal disease in pediatric patients is uncommon. Compared with adults, children are much less likely to develop complications of infection such as duodenal and gastric ulcers. Furthermore, there is no evidence that <em>H</em>. <em>pylori</em> infection causes functional abdominal pain in children and that treatment improves functional gastrointestinal pain-related symptoms. As a result, different strategies for screening, diagnosis, and treatment of <em>H</em>. <em>pylori</em> should be used for children than for adults.</p><p>This topic review will provide an overview of screening, diagnosis, and management of <em>H</em>. <em>pylori</em> infection in children and adolescents, highlighting differences in management compared with adults. Evaluation and management of <em>H</em>. <em>pylori</em> in adults are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/18.html" rel="external">"Indications and diagnostic tests for Helicobacter pylori infection in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7.html" rel="external">"Treatment regimens for Helicobacter pylori in adults"</a>.)</p><p class="headingAnchor" id="H2478184603"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The prevalence of <em>H</em>. <em>pylori</em> is declining worldwide, and particularly in resource-abundant settings. However, <em>H</em>. <em>pylori</em> remains one of the most common human infections worldwide. The prevalence varies widely according to different geographic areas and within specific regions as well as by age and socioeconomic factors. In low- and middle-income countries or other disadvantaged populations, up to 75 percent of the population is infected, likely due to environmental factors including crowding and problems with water sanitation and transmission of the organism by fecal-oral, oral-oral, and gastro-oral routes [<a href="#rid1">1-3</a>].</p><p>Among children (&lt;18 years), the global prevalence of <em>H</em>. <em>pylori</em> infection rates is 32 to 36 percent; prevalence ranges from &lt;5 percent (eg, in Scandinavian countries) to &gt;70 percent (eg, in several countries in Africa [Benin, Nigeria] and Latin America [Peru]), with rates of 30 to 40 percent in the United States, Canada, and the United Kingdom [<a href="#rid4">4</a>]. When grouped by socioeconomic regions (as defined by the World Bank), infection rates among children are approximately 22 percent in high-income countries and 43 percent in low- and middle-income countries. The prevalence of <em>H</em>. <em>pylori</em> infection is associated with lower socioeconomic status of the family in which a child is raised, higher number of persons sharing a home, room sharing, lack of access to a sewer system, drinking water that is not boiled or treated, and having household members with <em>H</em>. <em>pylori</em> infection [<a href="#rid4">4,5</a>]. The lower prevalence in children compared with adults is likely due to socioeconomic improvements (ie, in infrastructure) rather than newly acquired infections as adults. Similarly, socioeconomic factors likely contribute to the decreasing rates of <em>H</em>. <em>pylori</em> infection over time in many regions. In some settings, <em>H</em>. <em>pylori</em> infection rates may also be influenced by earlier diagnosis and treatment of <em>H</em>. <em>pylori</em> among adults, driven by the increasingly recognized relationship between <em>H</em>. <em>pylori</em> infection and gastric cancer [<a href="#rid6">6,7</a>].</p><p><em>H</em>. <em>pylori</em> infection is predominantly acquired during early childhood. Most infections occur before 10 years of age [<a href="#rid1">1,2,5,8,9</a>], especially in resource-limited countries where infection acquisition often occurs prior to three years of age [<a href="#rid10">10-13</a>]. As an example, a study in Irish children demonstrated that the greatest risk period for acquiring infection was prior to three years of age and the risk for new primary infection decreased after five years of age [<a href="#rid14">14</a>].</p><p>Children also have high rates of reinfection if the initial <em>H</em>. <em>pylori</em> infection is eradicated. Reinfection rates are approximately 20 percent or more in high-prevalence populations [<a href="#rid15">15</a>]. Risk factors for reinfection are similar to those for primary infection [<a href="#rid16">16,17</a>]. For older children, household contact with siblings younger than five years is a risk factor for reinfection [<a href="#rid18">18-20</a>]. In contrast with children, reinfection is rare after successful eradication in adults. (See  <a class="medical medical_review" href="/z/d/html/16.html" rel="external">"Bacteriology and epidemiology of Helicobacter pylori infection"</a>.)</p><p class="headingAnchor" id="H2561044558"><span class="h1">NATURAL HISTORY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Phases of infection</strong> – The natural history of <em>H</em>. <em>pylori</em> infection appears to occur in phases, at least in adults with newly acquired infection. Adult volunteers who ingest a dose of <em>H</em>. <em>pylori</em> experience:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Initial phase – Intense bacterial proliferation with gastric inflammation, sometimes associated with transient upper gastrointestinal symptoms and hypochlorhydria.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chronic phase – The inflammatory response subsides to either a chronic diffuse superficial gastritis with normal or reduced gastric acid production, or antral-predominant gastritis, which results in increased gastric acid production and increased risk for peptic ulcer disease. For unclear reasons, some chronically infected individuals remain free of symptoms for years or even a lifetime. (See  <a class="medical medical_review" href="/z/d/html/31.html" rel="external">"Acute and chronic gastritis due to Helicobacter pylori"</a>.)</p><p></p><p class="bulletIndent1">Whether a similar pattern of transient gastroduodenal inflammation occurs after <em>H</em>. <em>pylori</em> acquisition in children or in populations in high-endemic regions remains unclear. However, indirect evidence suggests that <em>H</em>. <em>pylori</em> infection in children is associated with limited clinical symptoms, a different phenotype of gastric inflammation than that in adults, and/or biomarkers of gastric or intestinal inflammation and intestinal permeability [<a href="#rid21">21,22</a>]. (See  <a class="medical medical_review" href="/z/d/html/31.html" rel="external">"Acute and chronic gastritis due to Helicobacter pylori"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of persistent infection</strong> – The likelihood that primary <em>H</em>. <em>pylori</em> infection persists varies depending on the child's age and the population studied. Persistent infection is most common for young children in populations where <em>H</em>. <em>pylori</em> is endemic [<a href="#rid2">2,23</a>]. As an example, in a study of children in Chile, two-thirds of children who acquired the infection during the first five years of life become persistently infected [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Protective factors</strong> – Innate factors that may protect against <em>H</em>. <em>pylori</em> infection (eg, <em>TLR4</em> gene polymorphisms) have been described but not firmly established [<a href="#rid24">24</a>].</p><p></p><p class="headingAnchor" id="H18820461"><span class="h1">CLINICAL MANIFESTATIONS AND CONSEQUENCES</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptoms and signs</strong> – The majority of children infected with <em>H</em>. <em>pylori</em> are asymptomatic (ie, no symptoms such as abdominal pain that are reported to the parents or health care provider). Most children with infection have gastric mucosal inflammation, typically described as chronic-active and/or nodular gastritis  (<a class="graphic graphic_picture graphicRef135155" href="/z/d/graphic/135155.html" rel="external">picture 1</a>), which is more common in children than in adults [<a href="#rid25">25-29</a>]. In most cases, the nodular gastritis is asymptomatic and complications of infection do not occur. However, in a small number of cases, frank mucosal erosions and duodenal or, to a lesser extent, gastric ulcers develop.</p><p></p><p class="bulletIndent1">If gastroduodenal ulcers develop, these can cause epigastric abdominal pain. However, children with gastric or duodenal ulcers more often have alarm signs (eg, occult blood in stool, weight loss or vomiting, or nighttime wakening with pain) that distinguish them from children with functional abdominal pain [<a href="#rid30">30-33</a>]. Therefore, screening for <em>H</em>. <em>pylori</em> infection is <strong>not</strong> recommended for children with a typical presentation of functional abdominal pain without alarm signs, as discussed below. (See <a class="local">'Indications for testing in children'</a> below and  <a class="medical medical_review" href="/z/d/html/111.html" rel="external">"Chronic abdominal pain in children and adolescents: Approach to the evaluation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse consequences of </strong><strong><em>H</em></strong><strong>. </strong><strong><em>pylori</em></strong><strong> infection</strong> – <em>H</em>. <em>pylori</em> infection is strongly associated with peptic ulcer disease in children, as it is in adults [<a href="#rid34">34</a>]. It is also associated with mucosa-associated lymphoid tissue (MALT) lymphoma [<a href="#rid35">35-37</a>], chronic (but not acute) immune thrombocytopenic (ITP) purpura [<a href="#rid38">38-46</a>], and iron deficiency anemia that is refractory to treatment [<a href="#rid47">47-49</a>], based on low-quality evidence. These associations form the indications for testing in children. (See <a class="local">'Indications for testing in children'</a> below.)</p><p></p><p class="bulletIndent1">By contrast, in adults, chron<em>ic</em> <em>H</em>. <em>pylori</em> infection is associated with functional dyspepsia in addition to the above conditions. There is also an association, and likely causative link, between <em>H</em>. <em>pylori</em> infection and iron deficiency in adults [<a href="#rid50">50</a>]. <em>H</em>. <em>pylori</em> infection is an important risk factor for gastric cancer in adults [<a href="#rid50">50,51</a>], although the overall risk of gastric cancer in infected individuals is low. These associations inform the broader indications f<em>or</em> <em>H</em>. <em>pylori</em> testing in adults as well as what has been termed a "screen and treat" management strategy. (See  <a class="medical medical_review" href="/z/d/html/18.html" rel="external">"Indications and diagnostic tests for Helicobacter pylori infection in adults"</a> and  <a class="medical medical_review" href="/z/d/html/17.html" rel="external">"Association between Helicobacter pylori infection and duodenal ulcer"</a> and  <a class="medical medical_review" href="/z/d/html/2514.html" rel="external">"Association between Helicobacter pylori infection and gastrointestinal malignancy"</a> and  <a class="medical medical_review" href="/z/d/html/11.html" rel="external">"Helicobacter pylori and gastroesophageal reflux disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Possible benefits of </strong><strong><em>H</em></strong><strong>. </strong><strong><em>pylori</em></strong><strong> infection</strong> – Epidemiologic studies suggest an inverse association between <em>H</em>. <em>pylori</em> infection and atopic diseases in children [<a href="#rid52">52-54</a>]. However, this association likely reflects the fact that <em>H</em>. <em>pylori</em> infection has declined and, conversely, that allergic or atopic diseases have increased significantly. Thus, <em>H</em>. <em>pylori</em> is probably a surrogate epidemiologic marker for infrastructure improvement rather than a primary factor that protects against atopic disease. Inverse associations with <em>H</em>. <em>pylori</em> infection have also been suggested for inflammatory bowel disease [<a href="#rid55">55,56</a>], celiac disease [<a href="#rid57">57,58</a>], and eosinophilic esophagitis [<a href="#rid59">59,60</a>], all of which have increasing prevalence and incidence. Although chronic <em>H</em>. <em>pylori</em> infection sometimes reduces gastric acid production, it does not appear to be protective against gastroesophageal reflux or esophageal or proximal gastric cancer [<a href="#rid61">61</a>]. (See  <a class="medical medical_review" href="/z/d/html/2243.html" rel="external">"Clinical manifestations and diagnosis of eosinophilic esophagitis (EoE)", section on 'Epidemiology'</a> and  <a class="medical medical_review" href="/z/d/html/11.html" rel="external">"Helicobacter pylori and gastroesophageal reflux disease"</a>.)</p><p></p><p class="headingAnchor" id="H1259022905"><span class="h1">EVALUATION</span></p><p class="headingAnchor" id="H3522261090"><span class="h2">Indications for testing in children</span><span class="headingEndMark"> — </span>Our approach to testing for <em>H</em>. <em>pylori</em> infection in children is outlined below. If the test for active infection is positive, we take steps to eradicate the infection.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definite indications</strong> – Important indications for testing f<em>or</em> <em>H</em>. <em>pylori</em> in children are:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Peptic ulcer disease (ie, gastric or duodenal ulcers)</strong> – Test all children with peptic ulcer disease. This condition is clearly associ<em>ated</em> <em>with</em> <em>H</em>. <em>pylori</em> infection in children, as it is in adults, although other factors such as nonsteroidal antiinflammatory drugs may contribute [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Family history of gastric cancer</strong> – Test for <em>H</em>. <em>pylori</em> in children who have first-degree relatives with gastric cancer. Chronic <em>H</em>. <em>pylori</em> infection is the most important risk factor for development of gastric cancer, and studies demonstrate that eradication is beneficial for patients with a first-degree relative with gastric cancer in <em>H</em>. <em>pylori</em>-infected adult populations [<a href="#rid51">51</a>]. (See  <a class="medical medical_review" href="/z/d/html/2514.html" rel="external">"Association between Helicobacter pylori infection and gastrointestinal malignancy"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mucosa-associated lymphoid tissue (MALT) lymphoma</strong> – Test all children with MALT lymphoma. Several case reports in children describe MALT lymphoma associated with <em>H</em>. <em>pylori</em>, which resolved after treatment of the infection, and similar cases have been described in adults [<a href="#rid35">35-37</a>]. Although this is low-quality evidence, the potential benefit of this treatment is substantially higher than its risks. (See  <a class="medical medical_review" href="/z/d/html/2514.html" rel="external">"Association between Helicobacter pylori infection and gastrointestinal malignancy", section on 'Gastric lymphoma'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relative indications</strong> – <em>H</em>. <em>pylori</em> testing is also appropriate in selected children with the following conditions [<a href="#rid46">46</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chronic immune thrombocytopenia (ITP)</strong> – Test for <em>H</em>. <em>pylori</em> in children with chronic ITP but not acute ITP. Case reports describe improvement in chronic ITP after <em>H</em>. <em>pylori</em> eradication [<a href="#rid38">38-45</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Refractory iron deficiency anemia</strong> – Test for <em>H</em>. <em>pylori</em> in children with iron deficiency anemia that is refractory to treatment with iron supplementation and when other possible causes of refractory iron deficiency anemia (eg, celiac disease, inflammatory bowel disease, or eosinophilic gastrointestinal diseases) have been ruled out. Several case reports describe resolution of refractory iron deficiency anemia after eradication of <em>H</em>. <em>pylori</em> [<a href="#rid47">47-49,62,63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Testing not indicated</strong> – For children, diagnostic testing for <em>H</em>. <em>pylori</em> is <strong>not</strong> indicated for the following conditions:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chronic abdominal pain (without alarm signs)</p><p class="bulletIndent2"><span class="glyph">•</span>Gastroesophageal reflux disease or other peptic symptoms (regardless of whether it is responsive to acid suppression)</p><p class="bulletIndent2"><span class="glyph">•</span>Growth failure or short stature</p><p class="bulletIndent2"><span class="glyph">•</span>Iron deficiency anemia (initial presentation and without alarm signs)</p><p></p><p class="bulletIndent1">These conditions do not predict the presence of <em>H</em>. <em>pylori</em> infection in children, and, if <em>H</em>. <em>pylori</em> is detected, eradication is unlikely to improve symptoms. Moreover, poorly targeted treatment of <em>H</em>. <em>pylori</em> increases the risk for antibiotic resistance in the population. For some children with functional abdominal pain, a positive test may contribute to anxiety and worsen symptoms. Finally, if <em>H</em>. <em>pylori</em> is treated and eradicated, reinfection can occur, especially in young children and in high-prevalence countries [<a href="#rid16">16,17,64</a>].</p><p></p><p class="bulletIndent1">For children with epigastric abdominal pain or iron deficiency anemia, performing noninvasive tests for <em>H</em>. <em>pylori</em> is not indicated. Endoscopic evaluation may be indicated if certain alarm signs such as gastrointestinal bleeding, persistent vomiting, or anorexia are present. The goal of the endoscopy is to determine the cause of the symptoms, which include several gastrointestinal conditions in addition to <em>H</em>. <em>pylori</em>-related gastroduodenal disease [<a href="#rid65">65</a>]. If endoscopy is performed, then the decision to test for <em>H</em>. <em>pylori</em> depends on the endoscopic findings (ie, whether peptic ulcer disease or gastric nodularity are identified). (See  <a class="medical medical_review" href="/z/d/html/111.html" rel="external">"Chronic abdominal pain in children and adolescents: Approach to the evaluation", section on 'Patients with alarm findings'</a>.)</p><p></p><p>Indications for <em>H</em>. <em>pylori</em> testing in adults are broader due to stronger evidence for disease associations in this population and lower rates of reinfection. (See  <a class="medical medical_review" href="/z/d/html/18.html" rel="external">"Indications and diagnostic tests for Helicobacter pylori infection in adults", section on 'Indications for testing'</a>.)</p><p class="headingAnchor" id="H4208571967"><span class="h2">How to test</span></p><p class="headingAnchor" id="H4021570237"><span class="h3">Pretesting conditions</span><span class="headingEndMark"> — </span>Ideally, patients should have no exposure to antibiotics for at least four weeks, no proton pump inhibitors (PPIs) for at least two weeks, and no histamine 2 receptor antagonists for at least one day before undertaking <em>H</em>. <em>pylori</em> testing [<a href="#rid65">65</a>]. Exposure to these drugs decreases the sensitivity of any of the below tests for active infection.</p><p class="headingAnchor" id="H2243213636"><span class="h3">Endoscopic tests (recommended)</span><span class="headingEndMark"> — </span>Endoscopic tests should generally be used for diagnosis of <em>H</em>. <em>pylori</em> in children, rather than noninvasive tests [<a href="#rid65">65</a>]. Endoscopic testing for <em>H</em>. <em>pylori</em> is appropriate because the indication for testing usually arises during a diagnostic endoscopy, when peptic ulcer disease or nodular gastritis are recognized. Moreover, endoscopic-based tests permit antibiotic sensitivity testing and provide the most diagnostic certainty compared with noninvasive tests.</p><p>When endoscopic testing for <em>H</em>. <em>pylori</em> is undertaken, at least six gastric biopsies should be performed, with samples for histology, rapid urease testing, and H<em>. </em>pylori culture. Where available, a molecular-based test (polymerase chain reaction [PCR] or fluorescence in situ hybridization [FISH]) can be substituted for the rapid urease test. These molecular tests are more accurate than the rapid urease test in the setting of active upper gastrointestinal bleeding [<a href="#rid66">66,67</a>].</p><p>Most children with H<em>. </em>pylori infection have both endoscopic (grossly visible changes such as nodularity, hyperemia, and edema  (<a class="graphic graphic_picture graphicRef135155" href="/z/d/graphic/135155.html" rel="external">picture 1</a>)) and histologic evidence of gastritis  (<a class="graphic graphic_picture graphicRef131611" href="/z/d/graphic/131611.html" rel="external">picture 2</a>), but some have normal-appearing mucosa [<a href="#rid68">68</a>]. Histopathology should be scored using the updated Sydney System classification for gastritis [<a href="#rid65">65</a>]. In addition, foveolar hyperplasia is a common characteristic of <em>H</em>. <em>pylori</em>-associated gastritis [<a href="#rid69">69</a>].</p><p class="headingAnchor" id="H1784154027"><span class="h3">Noninvasive tests (supportive)</span><span class="headingEndMark"> — </span>Noninvasive testing is <strong>not</strong> recommended for the initial diagnosis <em>of</em> <em>H</em>. <em>pylori</em> in children. An exception for noninvasive testing is for the diagnosis <em>of</em> <em>H</em>. <em>pylori</em> in a patient with ITP or family history of gastric cancer in a first-degree relative because these children would not otherwise require an endoscopy [<a href="#rid65">65</a>]. Noninvasive tests are also appropriate to confirm eradication after treatment. (See <a class="local">'Follow-up'</a> below.)</p><p>When noninvasive testing is performed, either of the following may be used:</p><p class="bulletIndent1"><span class="glyph">●</span><em>H</em>. <em>pylori</em> stool antigen assay – Consisting of a two-step monoclonal enzyme immunoassay. This test is valid for all age groups and is preferred for younger children (rather than the urea breath test) [<a href="#rid70">70</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Urea breath test – This test is an acceptable alternative for children &gt;6 years who can cooperate with the testing protocol; it has a higher false-positive rate in younger or uncooperative children (due to contamination from oral urease-producing organisms).</p><p></p><p>In contrast with guidelines for children, noninvasive testing is often used for the initial diagnosis of <em>H</em>. <em>pylori</em> in adults (ie, where breath testing is a principle component of the algorithm for undiagnosed dyspepsia) [<a href="#rid71">71</a>]. This is because there are broader indications for <em>H</em>. <em>pylori</em> testing in adults, several of which do not also require endoscopy. (See  <a class="medical medical_review" href="/z/d/html/18.html" rel="external">"Indications and diagnostic tests for Helicobacter pylori infection in adults", section on 'Diagnostic tests'</a>.)</p><p class="headingAnchor" id="H1664435975"><span class="h3">Serology (not recommended)</span><span class="headingEndMark"> — </span>Serologic testing for <em>H</em>. <em>pylori</em> has no place in the management of <em>H</em>. <em>pylori</em> infection in children and is <strong>not</strong> recommended for either diagnosis or follow-up after treatment. These tests have poor sensitivity and specificity and, therefore, low positive predictive value in low-prevalence settings. In addition, these tests do not distinguish between active and past infection.</p><p class="headingAnchor" id="H18820470"><span class="h1">DIAGNOSIS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients undergoing upper endoscopy</strong> – The gold standard for diagnosis is based on tests on biopsies of the gastric antrum (see <a class="local">'Endoscopic tests (recommended)'</a> above). Criteria for the initial diagnosis of <em>H</em>. <em>pylori</em> infection in children are [<a href="#rid65">65</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Positive culture for <em>H</em>. <em>pylori</em>, <strong>or</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Evidence of <em>H</em>. <em>pylori</em> on histopathology <strong>plus</strong> one of the following biopsy-based tests (where available):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Rapid urease test</p><p class="bulletIndent3"><span class="glyph">-</span>Polymerase chain reaction (PCR)</p><p class="bulletIndent3"><span class="glyph">-</span>Fluorescence in situ hybridization (FISH)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If histopathology is positive and no other biopsy-based test is available, then a noninvasive test can be used to support the diagnosis</p><p></p><p class="bulletIndent1">Once the diagnosis is established, a noninvasive test (urea breath or stool antigen test) can be used for follow-up testing post-treatment. (See <a class="local">'Follow-up'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients in whom endoscopy is not indicated or is contraindicated</strong> – A urea breath test or stool antigen assay (preferably monoclonal test and not polyclonal or rapid office-based test) provide reliable evidence of active infection. (See <a class="local">'Noninvasive tests (supportive)'</a> above.)</p><p></p><p class="bulletIndent1">These tests can be used to diagno<em>se</em> <em>H</em>. <em>pylori</em> infection in children under the following limited circumstances:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with a family history of gastric cancer (see <a class="local">'Noninvasive tests (supportive)'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Follow-up testing to confirm eradication after treatment for documented <em>H</em>. <em>pylori</em> infection (see <a class="local">'Follow-up'</a> below)</p><p></p><p class="bulletIndent1">This limited use of noninvasive diagnosis in children reflects the narrow indications for treatment in this age group, for whom treatment is recommended only if there is strong evidence of <em>H</em>. <em>pylori</em>-related pathology. (See <a class="local">'Indications for treatment in children'</a> below.)</p><p></p><p class="headingAnchor" id="H18820478"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H1479114971"><span class="h2">Indications for treatment in children</span><span class="headingEndMark"> — </span>In the pediatric age group, <em>H</em>. <em>pylori</em> infection should only be treated if there is a strong suspicion of <em>H</em>. <em>pylori</em>-related disease complications; indications are the same as those for diagnostic testing. (See <a class="local">'Indications for testing in children'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definite indications</strong> – The primary indications for treatment are duodenal or gastric ulcers with biopsy-proven <em>H</em>. <em>pylori</em> infection. For these children, it is likely that the peptic ulcer disease is related to <em>H</em>. <em>pylori</em> and treatment of the infection will be beneficial [<a href="#rid34">34,72,73</a>]. The combination of mucosa-associated lymphoid tissue (MALT) lymphoma with <em>H</em>. <em>pylori</em> infection is also an indication for treatment of the infection, although this is very rare and based only on case reports describing resolution of the lymphoma after treatment for <em>H</em>. <em>pylori</em>. Having a first-degree relative with gastric cancer is now an indication for testing for <em>H</em>. <em>pylori</em> infection because evidence demonstrates a reduction in gastric cancer incidence following <em>H</em>. <em>pylori</em> eradication, with no change in all-cause mortality [<a href="#rid51">51</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relative indications</strong> – Relative indications for treatment are incidental <em>H</em>. <em>pylori</em> infection identified during endoscopy and refractory iron deficiency anemia. For these patients, the decision to treat should be made by the patient and their family after a detailed discussion of the potential benefits and risks of treatment. The family should understand that treatment may not improve symptoms (especially nonspecific abdominal pain), the possibility of treatment failure or reinfection, and the need for close adherence to a complicated treatment regimen for two weeks.</p><p></p><p>Similarly, the situation occasionally arises where noninvasive testing for <em>H</em>. <em>pylori</em> (eg, stool antigen test) has been performed for a child with functional abdominal pain, although this is not a recommended diagnostic approach (see <a class="local">'Noninvasive tests (supportive)'</a> above). If the result is positive, the clinician should discuss the pros and cons of further investigation (eg, endoscopy) and/or treatment with the patient and their family.</p><p class="headingAnchor" id="H1338735669"><span class="h2">Anticipatory guidance</span><span class="headingEndMark"> — </span>For all patients and their families, provide the following anticipatory guidance before embarking on treatment:</p><p class="bulletIndent1"><span class="glyph">●</span>Treatment fails to eradicate <em>H</em>. <em>pylori</em> in at least 20 percent of patients in the real-world setting.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Effective treatment requires close adherence to a regimen of at least three medicines for two weeks. Missing doses increases the risk for treatment failure and antibiotic resistance [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Even if eradication is successful, some patients may be reinfected, especially young children.</p><p></p><p class="headingAnchor" id="H939569681"><span class="h2">Treatment regimens</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Selection of regimen</strong> – Appropriate treatment regimens for children are outlined in the algorithm  (<a class="graphic graphic_algorithm graphicRef141530" href="/z/d/graphic/141530.html" rel="external">algorithm 1</a>) tables  (<a class="graphic graphic_table graphicRef130667 graphicRef130668" href="/z/d/graphic/130667.html" rel="external">table 1A-B</a>) [<a href="#rid65">65</a>].</p><p></p><p class="bulletIndent1">Because antibiotic resistance is common, selection of an appropriate regimen should be made based upon antibiotic susceptibility testing for the individual patient, if at all possible [<a href="#rid65">65,73</a>].</p><p></p><p class="bulletIndent1">If antibiotic susceptibility testing is not available, then quadruple therapy with bismuth should be first-line therapy (where bismuth is available). Eradication rates with bismuth-based quadruple therapy are superior to high-dose <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">amoxicillin</a> triple regimen, based on indirect comparisons in adults with risk factors for macrolide resistance and one small study in Korean children [<a href="#rid65">65,73-77</a>]. The patient's history of antibiotic therapy is also relevant to selecting an appropriate regimen, given the high likelihood of induced resistance. If there is a history of any prior treatment with macrolides (<a class="drug drug_pediatric" data-topicid="13165" href="/z/d/drug information/13165.html" rel="external">clarithromycin</a>, <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">azithromycin</a>, or others), clarithromycin-based regimens should be avoided. Prior use of amoxicillin does not preclude its use, since amoxicillin resistance is uncommon. (See  <a class="medical medical_review" href="/z/d/html/7.html" rel="external">"Treatment regimens for Helicobacter pylori in adults", section on 'Patients with risk factors for macrolide resistance'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of therapy</strong> – We suggest a 14-day course for any of these regimens, based on several lines of indirect evidence: For triple therapy, a 14-day course is associated with significantly higher eradication rates compared with shorter courses of therapy, based primarily on studies in adults [<a href="#rid75">75,78</a>]. For bismuth-based quadruple therapy, a meta-analysis conducted in 2013 showed only marginal benefits of a 14-day versus a shorter treatment course [<a href="#rid78">78</a>]. Moreover, the benefit of the 14-day course is expected to increase with the prevalence of antibiotic-resistant strains, which continues to increase since these studies were conducted [<a href="#rid77">77</a>]. Adherence to therapy is critical to optimize eradication and reduce the risk of inducing antibiotic resistance [<a href="#rid65">65,79</a>].</p><p></p><p class="headingAnchor" id="H3308495181"><span class="h1">FOLLOW-UP</span></p><p class="headingAnchor" id="H719261484"><span class="h2">Confirmation of eradication</span><span class="headingEndMark"> — </span>All children who have been treated for <em>H</em>. <em>pylori</em> should undergo follow-up testing to determine whether the infection was eradicated [<a href="#rid65">65</a>]. This testing should be performed at least four weeks after completion of the treatment using a noninvasive test (unless a follow-up endoscopy is otherwise indicated) [<a href="#rid65">65</a>]. Appropriate tests for this purpose are the urea breath test or stool antigen testing [<a href="#rid80">80</a>]. For young children, stool antigen tests are probably more accurate than breath testing. (See <a class="local">'Noninvasive tests (supportive)'</a> above.)</p><p>Antibody testing for <em>H</em>. <em>pylori</em> (in blood, urine, or saliva) is not recommended for diagnosis or follow-up, due to poor sensitivity and specificity and because these tests do not distinguish between active and past infection. (See <a class="local">'Serology (not recommended)'</a> above.)</p><p>If the follow-up test is negative, then no further testing is needed. If the patient remains symptomatic, further evaluation should be tailored to the symptoms and this may include upper endoscopy. Additional courses of treatment should be given only if there is laboratory evidence of persistent <em>H</em>. <em>pylori</em> infection; treatment should not be given empirically based on symptoms.</p><p class="headingAnchor" id="H4175822882"><span class="h2">Rescue therapy for persistent <i>H. pylori</i> infection</span><span class="headingEndMark"> — </span>Children who have persistent <em>H</em>. <em>pylori</em> infection after completing initial therapy should be treated again with an alternate regimen. Treatment options are limited compared with those for adults since some antibiotic options are not approved or not appropriate for use in children [<a href="#rid65">65</a>].</p><p>Examples of appropriate rescue regimens are shown in the table  (<a class="graphic graphic_table graphicRef130669" href="/z/d/graphic/130669.html" rel="external">table 2</a>). The rescue therapy should be tailored to the initial antibiotic susceptibility patterns (if known). If either <a class="drug drug_pediatric" data-topicid="13165" href="/z/d/drug information/13165.html" rel="external">clarithromycin</a> or <a class="drug drug_pediatric" data-topicid="12606" href="/z/d/drug information/12606.html" rel="external">metronidazole</a> was included in the initial regimen, that antibiotic should be avoided in the rescue regimen because use of these antibiotics often induces secondary resistance. Similarly, clarithromycin should be avoided if there is a history of any prior treatment with macrolides and <a class="drug drug_pediatric" data-topicid="12549" href="/z/d/drug information/12549.html" rel="external">levofloxacin</a> should be avoided if there is a history of any prior treatment with fluoroquinolones. By contrast, resistance to <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">amoxicillin</a> or <a class="drug drug_pediatric" data-topicid="12830" href="/z/d/drug information/12830.html" rel="external">tetracycline</a> is rare and regimens containing these medications can be considered for subsequent rescue therapies. If the patient is thought to have a penicillin allergy but has no history of anaphylaxis, penicillin allergy testing should be considered to confirm or refute penicillin as an allergy and potentially enable its use.</p><p>When <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">amoxicillin</a> or <a class="drug drug_pediatric" data-topicid="12606" href="/z/d/drug information/12606.html" rel="external">metronidazole</a> is used for rescue therapy (ie, if a prior attempt at treatment was unsuccessful), we typically use higher doses (metronidazole 50 mg/kg/day divided three times daily and amoxicillin 75 mg/kg/day divided three or four times daily to avoid low trough levels). Other antibiotic doses are similar to those used for initial therapy, as shown in the table  (<a class="graphic graphic_table graphicRef130668" href="/z/d/graphic/130668.html" rel="external">table 1B</a>).</p><p>In addition to selecting a regimen tailored to the antibiotic susceptibility testing and antibiotic history of the individual patient, clinicians should attempt to identify other contributing factors, including inadequate adherence to therapy and insufficient gastric acid suppression, which can occur even with proton pump inhibitors (PPIs). Because inadequate acid suppression is associated with failure of <em>H</em>. <em>pylori</em> eradication, high-dose and more potent PPIs, if available, should be considered in cases of refractory <em>H</em>. <em>pylori</em> infection.</p><p>If two treatment attempts are unsuccessful despite good adherence to the regimen, we suggest repeat endoscopy and repeat antibiotic susceptibility testing of the <em>H</em>. <em>pylori</em> strain to guide the selection of subsequent regimens [<a href="#rid81">81</a>]. In some cases, there should be shared decision-making regarding ongoing attempts to eradicate <em>H</em>. <em>pylori</em>. The potential benefits of <em>H</em>. <em>pylori</em> eradication should be weighed carefully against the likelihood of adverse effects and inconvenience of repeated exposure to antibiotics and high-dose acid suppression, particularly in vulnerable populations.</p><p>Alternative regimens that have been studied in adults with <em>H</em>. <em>pylori</em> infection include acid suppression with potassium-competitive acid blockers such as vonoprazan, rather than PPIs. Randomized studies in adults and prospective studies in adolescents suggest possible benefits over PPI-based regimens [<a href="#rid82">82,83</a>]. These strategies are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7.html" rel="external">"Treatment regimens for Helicobacter pylori in adults", section on 'Adjuvant therapies with unclear role'</a>.)</p><p class="headingAnchor" id="H3342031142"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110246.html" rel="external">"Society guideline links: <i>Helicobacter pylori</i>"</a>.)</p><p class="headingAnchor" id="H4042371406"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations and consequences</strong> – <em>H</em>. <em>pylori</em> infection in children is usually asymptomatic. Rarely, <em>H</em>. <em>pylori</em> causes peptic ulcer disease in children, which can manifest as epigastric abdominal pain. However, most children with peptic ulcer disease will have alarm signs (eg, nighttime wakening, occult blood in stool, weight loss or vomiting) that distinguish them from children with functional abdominal pain. (See <a class="local">'Clinical manifestations and consequences'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Testing indicated</strong> – The only definite indications for diagnostic testing for <em>H</em>. <em>pylori</em> in children are duodenal and gastric ulcers, ie, peptic ulcer disease, first-degree relative with gastric cancer, and, possibly, mucosa-associated lymphoid tumor (MALT) lymphoma. Relative indications include incidental findings of histopathologic or nodular gastritis during endoscopy  (<a class="graphic graphic_picture graphicRef135155" href="/z/d/graphic/135155.html" rel="external">picture 1</a>) and refractory iron deficiency anemia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Testing not indicated</strong> – Diagnostic testing for <em>H</em>. <em>pylori</em> is <strong>not</strong> indicated for patients with functional abdominal pain (in the absence of alarm signs such as occult blood in stool, weight loss, or vomiting) or other gastrointestinal symptoms, newly diagnosed iron deficiency anemia, or poor growth. These conditions do not predict the presence of <em>H</em>. <em>pylori</em> infection in children. If <em>H</em>. <em>pylori</em> is detected, eradication is unlikely to improve symptoms and reinfection is common. Moreover, poorly targeted treatment of <em>H</em>. <em>pylori</em> increases the risk for antibiotic resistance in the population. (See <a class="local">'Indications for testing in children'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Technique</strong> – For initial diagnosis of <em>H</em>. <em>pylori</em> in children:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Before performing diagnostic testing, patients should have no recent exposure to antibiotics or acid-suppressing medications. (See <a class="local">'Pretesting conditions'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In most cases, endoscopic biopsy with confirmatory testing should be used, rather than noninvasive tests. Serology or other antibody-based tests are <strong>not</strong> recommended. (See <a class="local">'How to test'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic criteria</strong> – Criteria for the initial diagnosis of <em>H</em>. <em>pylori</em> infection in children are a positive culture for <em>H</em>. <em>pylori</em> or evidence of <em>H</em>. <em>pylori</em> on histopathology plus a rapid urease test (or molecular testing on a biopsy sample). A urea breath test or stool antigen assay can be used to diagnose <em>H</em>. <em>pylori</em> infection in children with a first-degree relative with gastric cancer or for follow-up testing after treatment. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Indications</strong> – We suggest treatment for any patient in whom the diagnosis of <em>H</em>. <em>pylori</em> infection has been confirmed (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>), provided that testing was performed for one of the indications listed above.</p><p></p><p class="bulletIndent2">For patients who are found to ha<em>v</em>e <em>H</em>. <em>pylori</em> infection as an incidental finding of infection at endoscopy, the decision to treat is individualized and depends on the reason for the endoscopy. Individualized decision-making about treatment or further evaluation is also required in the situation where noninvasive testing for <em>H</em>. <em>pylori</em> (eg. stool antigen test) has been performed in a child with functional abdominal pain and the test result is positive (this is not a recommended diagnostic approach). (See <a class="local">'Indications for treatment in children'</a> above.)</p><p></p><p class="bulletIndent2">If treatment is undertaken, it is important to educate the family that treatment may not improve symptoms (especially nonspecific abdominal pain) and the need for close adherence to a complicated treatment regimen for two weeks. (See <a class="local">'Anticipatory guidance'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Regimens</strong> – Appropriate regimens for treating <em>H</em>. <em>pylori</em> in children are outlined in the algorithm  (<a class="graphic graphic_algorithm graphicRef141530" href="/z/d/graphic/141530.html" rel="external">algorithm 1</a>) and tables  (<a class="graphic graphic_table graphicRef130667 graphicRef130668" href="/z/d/graphic/130667.html" rel="external">table 1A-B</a>). (See <a class="local">'Treatment regimens'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>We suggest a targeted treatment regimen based upon antibiotic susceptibility testing rather than an empiric regimen (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Targeted therapy is more likely to successfully eradicate the infection and less likely to cause adverse effects or induce antibiotic resistance.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If the strain is resistant to both <a class="drug drug_pediatric" data-topicid="13165" href="/z/d/drug information/13165.html" rel="external">clarithromycin</a> and <a class="drug drug_pediatric" data-topicid="12606" href="/z/d/drug information/12606.html" rel="external">metronidazole</a> or if antibiotic susceptibility is not known, we suggest quadruple therapy with bismuth, a proton pump inhibitor (PPI), and at least two antibiotics (typically <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">amoxicillin</a> and <a class="drug drug_pediatric" data-topicid="12830" href="/z/d/drug information/12830.html" rel="external">tetracycline</a> for children over the age of eight) rather than triple therapy with high-dose amoxicillin (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Quadruple therapy including bismuth generally has the highest eradication rates in populations with high risk for macrolide resistance, based primarily on studies in adults and on indirect comparisons with other regimens.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>We suggest a 14-day treatment course rather than a shorter course (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). This is based on evidence that a 14-day course is more effective for several specific treatment regimens and the increasing prevalence of antibiotic-resistant strains, for which a longer course of antibiotics is likely to be more effective. Adherence to the full course of therapy optimizes eradication and reduces the likelihood of inducing antibiotic resistance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Confirmation of eradication</strong> – All children who have been treated for <em>H</em>. <em>pylori</em> should undergo follow-up testing to determine whether the infection was eradicated. This testing should be performed at least four weeks after completion of the treatment, using a stool antigen assay or urea breath test (unless a follow-up endoscopy is otherwise indicated). (See <a class="local">'Confirmation of eradication'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rescue therapy</strong> – Children who have persistent <em>H</em>. <em>pylori</em> infection after completing initial therapy should be treated again with an alternate regimen (rescue therapy), as outlined in the table  (<a class="graphic graphic_table graphicRef130669" href="/z/d/graphic/130669.html" rel="external">table 2</a>). (See <a class="local">'Rescue therapy for persistent H. pylori infection'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Parkinson AJ, Gold BD, Bulkow L, et al. High prevalence of Helicobacter pylori in the Alaska native population and association with low serum ferritin levels in young adults. Clin Diagn Lab Immunol 2000; 7:885.</a></li><li><a class="nounderline abstract_t">Sinha SK, Martin B, Gold BD, et al. The incidence of Helicobacter pylori acquisition in children of a Canadian First Nations community and the potential for parent-to-child transmission. Helicobacter 2004; 9:59.</a></li><li><a class="nounderline abstract_t">Hooi JKY, Lai WY, Ng WK, et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology 2017; 153:420.</a></li><li><a class="nounderline abstract_t">Yuan C, Adeloye D, Luk TT, et al. The global prevalence of and factors associated with Helicobacter pylori infection in children: a systematic review and meta-analysis. Lancet Child Adolesc Health 2022; 6:185.</a></li><li><a class="nounderline abstract_t">Bauer S, Krumbiegel P, Richter M, et al. Influence of sociodemographic factors on Helicobacter pylori prevalence variability among schoolchildren in Leipzig, Germany. A long-term follow-up study. Cent Eur J Public Health 2011; 19:42.</a></li><li><a class="nounderline abstract_t">Corrigendum. Helicobacter 2019; 24:e12673.</a></li><li><a class="nounderline abstract_t">Boyanova L, Hadzhiyski P, Markovska R, et al. Prevalence of Helicobacter pylori is still high among symptomatic Bulgarian children. Acta Microbiol Immunol Hung 2019; 66:255.</a></li><li><a class="nounderline abstract_t">Glynn MK, Friedman CR, Gold BD, et al. Seroincidence of Helicobacter pylori infection in a cohort of rural Bolivian children: acquisition and analysis of possible risk factors. Clin Infect Dis 2002; 35:1059.</a></li><li><a class="nounderline abstract_t">Epplein M, Signorello LB, Zheng W, et al. Race, African ancestry, and Helicobacter pylori infection in a low-income United States population. Cancer Epidemiol Biomarkers Prev 2011; 20:826.</a></li><li><a class="nounderline abstract_t">McMillan M, Mackay WG, Williams CL, et al. Intrafamilial Genotyping of Helicobacter pylori from Faecal DNA. Gastroenterol Res Pract 2011; 2011:491035.</a></li><li><a class="nounderline abstract_t">Goodman KJ, Correa P, Mera R, et al. Effect of Helicobacter pylori infection on growth velocity of school-age Andean children. Epidemiology 2011; 22:118.</a></li><li><a class="nounderline abstract_t">Weck MN, Brenner H. Apparent incidence of Helicobacter pylori in adulthood: to what extent do new infections reflect misclassification? Helicobacter 2011; 16:266.</a></li><li><a class="nounderline abstract_t">Drumm B, Day AS, Gold B, et al. Helicobacter pylori and peptic ulcer: Working Group Report of the second World Congress of Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2004; 39 Suppl 2:S626.</a></li><li><a class="nounderline abstract_t">Rowland M, Daly L, Vaughan M, et al. Age-specific incidence of Helicobacter pylori. Gastroenterology 2006; 130:65.</a></li><li><a class="nounderline abstract_t">Nolen LD, Bruden D, Miernyk K, et al. H. pylori-associated pathologic findings among Alaska native patients. Int J Circumpolar Health 2018; 77:1510715.</a></li><li><a class="nounderline abstract_t">Sivapalasingam S, Rajasingham A, Macy JT, et al. Recurrence of Helicobacter pylori infection in Bolivian children and adults after a population-based "screen and treat" strategy. Helicobacter 2014; 19:343.</a></li><li><a class="nounderline abstract_t">Feydt-Schmidt A, Kindermann A, Konstantopoulos N, et al. Reinfection rate in children after successful Helicobacter pylori eradication. Eur J Gastroenterol Hepatol 2002; 14:1119.</a></li><li><a class="nounderline abstract_t">Halitim F, Vincent P, Michaud L, et al. High rate of Helicobacter pylori reinfection in children and adolescents. Helicobacter 2006; 11:168.</a></li><li><a class="nounderline abstract_t">Goodman KJ, Correa P. Transmission of Helicobacter pylori among siblings. Lancet 2000; 355:358.</a></li><li><a class="nounderline abstract_t">Miernyk KM, Bulkow LR, Gold BD, et al. Prevalence of Helicobacter pylori among Alaskans: Factors associated with infection and comparison of urea breath test and anti-Helicobacter pylori IgG antibodies. Helicobacter 2018; 23:e12482.</a></li><li><a class="nounderline abstract_t">Fahim SM, Das S, Gazi MA, et al. Helicobacter pylori infection is associated with fecal biomarkers of environmental enteric dysfunction but not with the nutritional status of children living in Bangladesh. PLoS Negl Trop Dis 2020; 14:e0008243.</a></li><li><a class="nounderline abstract_t">Lucero Y, Lagomarcino AJ, Torres JP, et al. Helicobacter pylori, clinical, laboratory, and noninvasive biomarkers suggestive of gastric damage in healthy school-aged children: A case-control study. Int J Infect Dis 2021; 103:423.</a></li><li><a class="nounderline abstract_t">O'Ryan ML, Rabello M, Cortés H, et al. Dynamics of Helicobacter pylori detection in stools during the first 5 years of life in Chile, a rapidly developing country. Pediatr Infect Dis J 2013; 32:99.</a></li><li><a class="nounderline abstract_t">Meliţ LE, Mărginean CO, Bănescu C, et al. The relationship between TLR4 rs4986790 and rs4986791 gene polymorphisms and Helicobacter pylori infection in children with gastritis. Pathol Res Pract 2019; 215:152692.</a></li><li><a class="nounderline abstract_t">Bahú Mda G, da Silveira TR, Maguilnick I, Ulbrich-Kulczynski J. Endoscopic nodular gastritis: an endoscopic indicator of high-grade bacterial colonization and severe gastritis in children with Helicobacter pylori. J Pediatr Gastroenterol Nutr 2003; 36:217.</a></li><li><a class="nounderline abstract_t">Hassall E, Dimmick JE. Unique features of Helicobacter pylori disease in children. Dig Dis Sci 1991; 36:417.</a></li><li><a class="nounderline abstract_t">Luzza F, Pensabene L, Imeneo M, et al. Antral nodularity identifies children infected with Helicobacter pylori with higher grades of gastric inflammation. Gastrointest Endosc 2001; 53:60.</a></li><li><a class="nounderline abstract_t">Sbeih F, Abdullah A, Sullivan S, Merenkov Z. Antral nodularity, gastric lymphoid hyperplasia, and Helicobacter pylori in adults. J Clin Gastroenterol 1996; 22:227.</a></li><li><a class="nounderline abstract_t">Broide E, Richter V, Mendlovic S, et al. Lymphoid follicles in children with Helicobacter pylori-negative gastritis. Clin Exp Gastroenterol 2017; 10:195.</a></li><li><a class="nounderline abstract_t">van Tilburg MAL. Can we treat visceral hypersensitivity in functional abdominal pain? Lancet Gastroenterol Hepatol 2017; 2:694.</a></li><li><a class="nounderline abstract_t">Pinto-Sanchez MI, Yuan Y, Bercik P, Moayyedi P. Proton pump inhibitors for functional dyspepsia. Cochrane Database Syst Rev 2017; 3:CD011194.</a></li><li><a class="nounderline abstract_t">Baaleman DF, Di Lorenzo C, Benninga MA, Saps M. The Effects of the Rome IV Criteria on Pediatric Gastrointestinal Practice. Curr Gastroenterol Rep 2020; 22:21.</a></li><li><a class="nounderline abstract_t">Pittayanon R, Yuan Y, Bollegala NP, et al. Prokinetics for functional dyspepsia. Cochrane Database Syst Rev 2018; 10:CD009431.</a></li><li><a class="nounderline abstract_t">Bontems P, Kalach N, Vanderpas J, et al. Helicobacter pylori Infection in European children with gastro-duodenal ulcers and erosions. Pediatr Infect Dis J 2013; 32:1324.</a></li><li><a class="nounderline abstract_t">Blecker U, McKeithan TW, Hart J, Kirschner BS. Resolution of Helicobacter pylori-associated gastric lymphoproliferative disease in a child. Gastroenterology 1995; 109:973.</a></li><li><a class="nounderline abstract_t">Ohno Y, Kosaka T, Muraoka I, et al. Remission of primary low-grade gastric lymphomas of the mucosa-associated lymphoid tissue type in immunocompromised pediatric patients. World J Gastroenterol 2006; 12:2625.</a></li><li><a class="nounderline abstract_t">Al Furaikh SS. Remission of high-grade B-cell lymphoma in a pediatric patient following Helicobacter pylori eradication. Pediatr Int 2011; 53:105.</a></li><li><a class="nounderline abstract_t">Franchini M, Veneri D. Helicobacter pylori-associated immune thrombocytopenia. Platelets 2006; 17:71.</a></li><li><a class="nounderline abstract_t">Jaing TH, Yang CP, Hung IJ, et al. Efficacy of Helicobacter pylori eradication on platelet recovery in children with chronic idiopathic thrombocytopenic purpura. Acta Paediatr 2003; 92:1153.</a></li><li><a class="nounderline abstract_t">Sato R, Murakami K, Watanabe K, et al. Effect of Helicobacter pylori eradication on platelet recovery in patients with chronic idiopathic thrombocytopenic purpura. Arch Intern Med 2004; 164:1904.</a></li><li><a class="nounderline abstract_t">Hayashi H, Okuda M, Aoyagi N, et al. Helicobacter pylori infection in children with chronic idiopathic thrombocytopenic purpura. Pediatr Int 2005; 47:292.</a></li><li><a class="nounderline abstract_t">Emilia G, Longo G, Luppi M, et al. Helicobacter pylori eradication can induce platelet recovery in idiopathic thrombocytopenic purpura. Blood 2001; 97:812.</a></li><li><a class="nounderline abstract_t">Rajantie J, Klemola T. Helicobacter pylori and idiopathic thrombocytopenic purpura in children. Blood 2003; 101:1660.</a></li><li><a class="nounderline abstract_t">Kurekci AE, Atay AA, Sarici SU, Ozcan O. Complete platelet recovery after treatment of Helicobacter pylori infection in a child with chronic immune thrombocytopenic purpura: a case report. Pediatr Hematol Oncol 2004; 21:593.</a></li><li><a class="nounderline abstract_t">Ikuse T, Toda M, Kashiwagi K, et al. Efficacy of Helicobacterpylori Eradication Therapy on Platelet Recovery in Pediatric Immune Thrombocytopenic Purpura-Case Series and a Systematic Review. Microorganisms 2020; 8.</a></li><li><a class="nounderline abstract_t">Kato S, Shimizu T, Toyoda S, et al. The updated JSPGHAN guidelines for the management of Helicobacter pylori infection in childhood. Pediatr Int 2020; 62:1315.</a></li><li><a class="nounderline abstract_t">DuBois S, Kearney DJ. Iron-deficiency anemia and Helicobacter pylori infection: a review of the evidence. Am J Gastroenterol 2005; 100:453.</a></li><li><a class="nounderline abstract_t">Konno M, Muraoka S, Takahashi M, Imai T. Iron-deficiency anemia associated with Helicobacter pylori gastritis. J Pediatr Gastroenterol Nutr 2000; 31:52.</a></li><li><a class="nounderline abstract_t">Russo-Mancuso G, Branciforte F, Licciardello M, La Spina M. Iron deficiency anemia as the only sign of infection with Helicobacter pylori: a report of 9 pediatric cases. Int J Hematol 2003; 78:429.</a></li><li><a class="nounderline abstract_t">Ko CW, Siddique SM, Patel A, et al. AGA Clinical Practice Guidelines on the Gastrointestinal Evaluation of Iron Deficiency Anemia. Gastroenterology 2020; 159:1085.</a></li><li><a class="nounderline abstract_t">Choi IJ, Kim CG, Lee JY, et al. Family History of Gastric Cancer and Helicobacter pylori Treatment. N Engl J Med 2020; 382:427.</a></li><li><a class="nounderline abstract_t">Blaser MJ, Chen Y, Reibman J. Does Helicobacter pylori protect against asthma and allergy? Gut 2008; 57:561.</a></li><li><a class="nounderline abstract_t">Serrano CA, Talesnik E, Peña A, et al. Inverse correlation between allergy markers and Helicobacter pylori infection in children is associated with elevated levels of TGF-β. Eur J Gastroenterol Hepatol 2011; 23:656.</a></li><li><a class="nounderline abstract_t">Zevit N, Balicer RD, Cohen HA, et al. Inverse association between Helicobacter pylori and pediatric asthma in a high-prevalence population. Helicobacter 2012; 17:30.</a></li><li><a class="nounderline abstract_t">Castaño-Rodríguez N, Kaakoush NO, Lee WS, Mitchell HM. Dual role of Helicobacter and Campylobacter species in IBD: a systematic review and meta-analysis. Gut 2017; 66:235.</a></li><li><a class="nounderline abstract_t">Wang WL, Xu XJ. Correlation between Helicobacter pylori infection and Crohn's disease: a meta-analysis. Eur Rev Med Pharmacol Sci 2019; 23:10509.</a></li><li><a class="nounderline abstract_t">Simondi D, Ribaldone DG, Bonagura GA, et al. Helicobacter pylori in celiac disease and in duodenal intraepithelial lymphocytosis: Active protagonist or innocent bystander? Clin Res Hepatol Gastroenterol 2015; 39:740.</a></li><li><a class="nounderline abstract_t">Narang M, Puri AS, Sachdeva S, et al. Celiac disease and Helicobacter pylori infection in children: Is there any Association? J Gastroenterol Hepatol 2017; 32:1178.</a></li><li><a class="nounderline abstract_t">Molina-Infante J, Gutierrez-Junquera C, Savarino E, et al. Helicobacter pylori infection does not protect against eosinophilic esophagitis: results from a large multicenter case-control study. Am J Gastroenterol 2018; 113:972.</a></li><li><a class="nounderline abstract_t">Shah SC, Tepler A, Peek RM Jr, et al. Association Between Helicobacter pylori Exposure and Decreased Odds of Eosinophilic Esophagitis-A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2019; 17:2185.</a></li><li><a class="nounderline abstract_t">Kumar S, Metz DC, Ginsberg GG, et al. Oesophageal and proximal gastric adenocarcinomas are rare after detection of Helicobacter pylori infection. Aliment Pharmacol Ther 2020; 51:781.</a></li><li><a class="nounderline abstract_t">Kato S, Gold BD, Kato A. The Resolution of Severe Iron-Deficiency Anemia After Successful Eradication of Helicobacter pylori in Teenagers. JPGN Rep 2022; 3:e238.</a></li><li><a class="nounderline abstract_t">Kato S, Gold BD, Kato A. Helicobacter pylori-Associated Iron Deficiency Anemia in Childhood and Adolescence-Pathogenesis and Clinical Management Strategy. J Clin Med 2022; 11.</a></li><li><a class="nounderline abstract_t">Morgan DR, Torres J, Sexton R, et al. Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities. JAMA 2013; 309:578.</a></li><li><a class="nounderline abstract_t">Jones NL, Koletzko S, Goodman K, et al. Joint ESPGHAN/NASPGHAN Guidelines for the Management of Helicobacter pylori in Children and Adolescents (Update 2016). J Pediatr Gastroenterol Nutr 2017; 64:991.</a></li><li><a class="nounderline abstract_t">Rimbara E, Sasatsu M, Graham DY. PCR detection of Helicobacter pylori in clinical samples. Methods Mol Biol 2013; 943:279.</a></li><li><a class="nounderline abstract_t">Saez J, Belda S, Santibáñez M, et al. Real-time PCR for diagnosing Helicobacter pylori infection in patients with upper gastrointestinal bleeding: comparison with other classical diagnostic methods. J Clin Microbiol 2012; 50:3233.</a></li><li><a class="nounderline abstract_t">Domșa AT, Lupușoru R, Gheban D, et al. Helicobacter pylori Gastritis in Children-The Link between Endoscopy and Histology. J Clin Med 2020; 9.</a></li><li><a class="nounderline abstract_t">Domșa AT, Gheban D, Lazăr C, et al. Particular Morphological Features in the Diagnosis of Pediatric Helicobacter pylori Gastritis: A Morphometry-Based Study. J Clin Med 2020; 9.</a></li><li><a class="nounderline abstract_t">Gisbert JP, Pajares JM. Stool antigen test for the diagnosis of Helicobacter pylori infection: a systematic review. Helicobacter 2004; 9:347.</a></li><li><a class="nounderline abstract_t">Moayyedi P, Lacy BE, Andrews CN, et al. ACG and CAG Clinical Guideline: Management of Dyspepsia. Am J Gastroenterol 2017; 112:988.</a></li><li><a class="nounderline abstract_t">Burgard M, Kotilea K, Mekhael J, et al. Evolution of Helicobacter pylori associated with gastroduodenal ulcers or erosions in children over the past 23 years: Decline or steady state? Helicobacter 2019; 24:e12629.</a></li><li><a class="nounderline abstract_t">Saleem N, Howden CW. Update on the Management of Helicobacter pylori Infection. Curr Treat Options Gastroenterol 2020; 18:476.</a></li><li><a class="nounderline abstract_t">Schwarzer A, Urruzuno P, Iwańczak B, et al. New effective treatment regimen for children infected with a double-resistant Helicobacter pylori strain. J Pediatr Gastroenterol Nutr 2011; 52:424.</a></li><li><a class="nounderline abstract_t">Hong J, Yang HR. Efficacy of Proton Pump Inhibitor-based Triple Therapy and Bismuth-based Quadruple Therapy for Helicobacter pylori Eradication in Korean Children. Pediatr Gastroenterol Hepatol Nutr 2012; 15:237.</a></li><li><a class="nounderline abstract_t">McNicholl AG, Bordin DS, Lucendo A, et al. Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients. Clin Gastroenterol Hepatol 2020; 18:89.</a></li><li><a class="nounderline abstract_t">Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol 2017; 112:212.</a></li><li><a class="nounderline abstract_t">Yuan Y, Ford AC, Khan KJ, et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev 2013; :CD008337.</a></li><li><a class="nounderline abstract_t">Schwarzer A, Bontems P, Urruzuno P, et al. Sequential Therapy for Helicobacter pylori Infection in Treatment-naïve Children. Helicobacter 2016; 21:106.</a></li><li><a class="nounderline abstract_t">Broekaert IJ, Borrelli O, Dolinsek J, et al. An ESPGHAN Position Paper on the Use of Breath Testing in Paediatric Gastroenterology. J Pediatr Gastroenterol Nutr 2022; 74:123.</a></li><li><a class="nounderline abstract_t">Shah SC, Iyer PG, Moss SF. AGA Clinical Practice Update on the Management of Refractory Helicobacter pylori Infection: Expert Review. Gastroenterology 2021; 160:1831.</a></li><li><a class="nounderline abstract_t">Chey WD, Mégraud F, Laine L, et al. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial. Gastroenterology 2022; 163:608.</a></li><li><a class="nounderline abstract_t">Kakiuchi T, Matsuo M, Endo H, et al. Efficacy and safety of vonoprazan-based regimen for Helicobacter pylori eradication therapy in Japanese adolescents: a prospective multicenter study. J Gastroenterol 2023; 58:196.</a></li></ol></div><div id="topicVersionRevision">Topic 14409 Version 8.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11063492" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : High prevalence of Helicobacter pylori in the Alaska native population and association with low serum ferritin levels in young adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15156905" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The incidence of Helicobacter pylori acquisition in children of a Canadian First Nations community and the potential for parent-to-child transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28456631" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35085494" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The global prevalence of and factors associated with Helicobacter pylori infection in children: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21526656" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Influence of sociodemographic factors on Helicobacter pylori prevalence variability among schoolchildren in Leipzig, Germany. A long-term follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31724265" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Corrigendum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30585499" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prevalence of Helicobacter pylori is still high among symptomatic Bulgarian children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12384839" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Seroincidence of Helicobacter pylori infection in a cohort of rural Bolivian children: acquisition and analysis of possible risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21357376" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Race, African ancestry, and Helicobacter pylori infection in a low-income United States population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21811496" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Intrafamilial Genotyping of Helicobacter pylori from Faecal DNA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21068668" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Effect of Helicobacter pylori infection on growth velocity of school-age Andean children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21762265" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Apparent incidence of Helicobacter pylori in adulthood: to what extent do new infections reflect misclassification?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15184762" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Helicobacter pylori and peptic ulcer: Working Group Report of the second World Congress of Pediatric Gastroenterology, Hepatology, and Nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16401469" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Age-specific incidence of Helicobacter pylori.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30157723" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : H. pylori-associated pathologic findings among Alaska native patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24830916" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Recurrence of Helicobacter pylori infection in Bolivian children and adults after a population-based "screen and treat" strategy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12362103" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Reinfection rate in children after successful Helicobacter pylori eradication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16684264" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : High rate of Helicobacter pylori reinfection in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10665555" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Transmission of Helicobacter pylori among siblings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29537130" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Prevalence of Helicobacter pylori among Alaskans: Factors associated with infection and comparison of urea breath test and anti-Helicobacter pylori IgG antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32324737" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Helicobacter pylori infection is associated with fecal biomarkers of environmental enteric dysfunction but not with the nutritional status of children living in Bangladesh.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33278617" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Helicobacter pylori, clinical, laboratory, and noninvasive biomarkers suggestive of gastric damage in healthy school-aged children: A case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23076385" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Dynamics of Helicobacter pylori detection in stools during the first 5 years of life in Chile, a rapidly developing country.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31690518" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The relationship between TLR4 rs4986790 and rs4986791 gene polymorphisms and Helicobacter pylori infection in children with gastritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12548057" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Endoscopic nodular gastritis: an endoscopic indicator of high-grade bacterial colonization and severe gastritis in children with Helicobacter pylori.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2007358" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Unique features of Helicobacter pylori disease in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11154490" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Antral nodularity identifies children infected with Helicobacter pylori with higher grades of gastric inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8724265" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Antral nodularity, gastric lymphoid hyperplasia, and Helicobacter pylori in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28860835" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Lymphoid follicles in children with Helicobacter pylori-negative gastritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28826626" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Can we treat visceral hypersensitivity in functional abdominal pain?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28271513" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Proton pump inhibitors for functional dyspepsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32193635" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The Effects of the Rome IV Criteria on Pediatric Gastrointestinal Practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30335201" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Prokinetics for functional dyspepsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24569306" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Helicobacter pylori Infection in European children with gastro-duodenal ulcers and erosions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7657127" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Resolution of Helicobacter pylori-associated gastric lymphoproliferative disease in a child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16688815" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Remission of primary low-grade gastric lymphomas of the mucosa-associated lymphoid tissue type in immunocompromised pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21342336" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Remission of high-grade B-cell lymphoma in a pediatric patient following Helicobacter pylori eradication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16421007" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Helicobacter pylori-associated immune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14632330" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Efficacy of Helicobacter pylori eradication on platelet recovery in children with chronic idiopathic thrombocytopenic purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15451766" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Effect of Helicobacter pylori eradication on platelet recovery in patients with chronic idiopathic thrombocytopenic purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15910453" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Helicobacter pylori infection in children with chronic idiopathic thrombocytopenic purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11157503" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Helicobacter pylori eradication can induce platelet recovery in idiopathic thrombocytopenic purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12560248" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Helicobacter pylori and idiopathic thrombocytopenic purpura in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15626015" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Complete platelet recovery after treatment of Helicobacter pylori infection in a child with chronic immune thrombocytopenic purpura: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32977477" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Efficacy of Helicobacterpylori Eradication Therapy on Platelet Recovery in Pediatric Immune Thrombocytopenic Purpura-Case Series and a Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32657507" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The updated JSPGHAN guidelines for the management of Helicobacter pylori infection in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15667507" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Iron-deficiency anemia and Helicobacter pylori infection: a review of the evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10896071" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Iron-deficiency anemia associated with Helicobacter pylori gastritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14704035" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Iron deficiency anemia as the only sign of infection with Helicobacter pylori: a report of 9 pediatric cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32810434" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : AGA Clinical Practice Guidelines on the Gastrointestinal Evaluation of Iron Deficiency Anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31995688" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Family History of Gastric Cancer and Helicobacter pylori Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18194986" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Does Helicobacter pylori protect against asthma and allergy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21629122" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Inverse correlation between allergy markers and Helicobacter pylori infection in children is associated with elevated levels of TGF-β.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22221613" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Inverse association between Helicobacter pylori and pediatric asthma in a high-prevalence population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26508508" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Dual role of Helicobacter and Campylobacter species in IBD: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31841206" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Correlation between Helicobacter pylori infection and Crohn's disease: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25956489" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Helicobacter pylori in celiac disease and in duodenal intraepithelial lymphocytosis: Active protagonist or innocent bystander?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27862319" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Celiac disease and Helicobacter pylori infection in children: Is there any Association?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29545632" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Helicobacter pylori infection does not protect against eosinophilic esophagitis: results from a large multicenter case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30659992" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Association Between Helicobacter pylori Exposure and Decreased Odds of Eosinophilic Esophagitis-A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32133681" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Oesophageal and proximal gastric adenocarcinomas are rare after detection of Helicobacter pylori infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37168639" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The Resolution of Severe Iron-Deficiency Anemia After Successful Eradication of Helicobacter pylori in Teenagers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36555966" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Helicobacter pylori-Associated Iron Deficiency Anemia in Childhood and Adolescence-Pathogenesis and Clinical Management Strategy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23403682" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28541262" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Joint ESPGHAN/NASPGHAN Guidelines for the Management of Helicobacter pylori in Children and Adolescents (Update 2016).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23104297" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : PCR detection of Helicobacter pylori in clinical samples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22837325" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Real-time PCR for diagnosing Helicobacter pylori infection in patients with upper gastrointestinal bleeding: comparison with other classical diagnostic methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32183130" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Helicobacter pylori Gastritis in Children-The Link between Endoscopy and Histology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33198263" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Particular Morphological Features in the Diagnosis of Pediatric Helicobacter pylori Gastritis: A Morphometry-Based Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15270750" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Stool antigen test for the diagnosis of Helicobacter pylori infection: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28631728" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : ACG and CAG Clinical Guideline: Management of Dyspepsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31282120" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Evolution of Helicobacter pylori associated with gastroduodenal ulcers or erosions in children over the past 23 years: Decline or steady state?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32837180" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Update on the Management of Helicobacter pylori Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21407111" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : New effective treatment regimen for children infected with a double-resistant Helicobacter pylori strain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24010093" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Efficacy of Proton Pump Inhibitor-based Triple Therapy and Bismuth-based Quadruple Therapy for Helicobacter pylori Eradication in Korean Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30978536" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28071659" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24338763" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Optimum duration of regimens for Helicobacter pylori eradication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26123402" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Sequential Therapy for Helicobacter pylori Infection in Treatment-naïve Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34292218" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : An ESPGHAN Position Paper on the Use of Breath Testing in Paediatric Gastroenterology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33524402" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : AGA Clinical Practice Update on the Management of Refractory Helicobacter pylori Infection: Expert Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35679950" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36528706" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Efficacy and safety of vonoprazan-based regimen for Helicobacter pylori eradication therapy in Japanese adolescents: a prospective multicenter study.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
